# Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

> **NCT04891172** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Dow University of Health Sciences** · enrollment: 310 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)

## Key facts

- **NCT ID:** NCT04891172
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-02
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2022-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891172, "Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04891172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*